Description
Blinatumomab Uses
Blincyto (Blinatumomab) is a bispecific CD19-directed CD3 T-cell engager used for the treatment of adults and children with:
- B-cell precursor ALL (Acute Lymphoblastic Leukemia) in first or second complete remission with MRD (Minimal Residual Disease) greater than or equal to 0.1%.
- Relapsed or refractory B-cell precursor ALL (Acute Lymphoblastic Leukemia).
Dosage: The recommended dose of Blincyto (blinatumomab injection) is administered as a continuous IV infusion for 28 consecutive days per cycle involving a 24/7 infusion followed by a 14 days off from infusion. The blincyto dose mainly depends on a patient’s actual body weight. Patients weighing over 45 kg should receive fixed doses of blincyto while patients weighing less than 45kg should receive doses of blincyto depending on their estimated body surface area.
Side Effects: The most commonly reported blincyto side effects include:
- Pyrexia
- Headache
- Infusion-related reactions
- Anemia
- Febrile neutropenia
- Thrombocytopenia
- Neutropenia
Warnings and Precautions:
- The blincyto injection should not be used in patients with known hypersensitivity to blinatumomab or to any component of the product formulation.
- Monitor patients receiving treatment with blincyto dosage for signs and symptoms of neurological toxicities.
- Patients with blincyto therapy should be monitored for signs and symptoms of infection and treated appropriately.
- Do not use vaccination with live virus vaccines for at least two weeks before starting blinatumomab treatment, while on treatment, and until immune recovery after the last cycle of therapy.
- Patients should be monitored for ALT (alanine aminotransferase), aspartate aminotransferase, gamma glutamyl transferase, and total blood bilirubin before starting and while on therapy with blinatumomab injection.